Test host directed therapies for COVID-19 via rapid, efficient, collaborative adaptive platform trials aimed at helping to prevent infection, slow or halt disease progression, and speed recovery.


Fully integrate major NHLBI networks under one organizational umbrella to ensure efficiencies; standardization; collaboration; and sharing of control groups (as appropriate), resources, and data.


NHLBI directed Program integrated with NIH ACTIV and conducted in collaboration with BARDA, Operation Warp Speed, and as appropriate, other Institutes of Health.

Latest News

New Item Image
07 October 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

Read More
New Item Image
05 October 2020
Cary man shares his battle with COVID-19

I was at the point where I didn't think I was going to make it. I was really bad, suffering with the breathing and everything...

Read More
New Item Image
27 September 2020
Medicine faculty part of ACTIV-3 trial team lauded by NIH

A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.

Read More